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ABSTRACT 
ARTERIAL AND VENOUS IMPACTS OF  
TRANSDERMALLY ADMINISTERED VASODILATORS  
ON THE LOCAL MICROVASCULATURE 
George Guo, B.A., Katherine Chuang, B.S., Nitin Sukumar, M.S., Feng Dai, Ph.D., 
David G. Silverman, M.D., Kirk Shelley, M.D/Ph.D., D.P.M., Aymen Alian, M.D. Yale 
University School of Medicine, Department of Anesthesiology, New Haven, CT.  
 
Microcirculatory function is an important component of cardiovascular pharmacology 
as related to cardiovascular dysfunction. We used photoplethysmography (PPG) to 
compare the microcirculatory effects of transdermal patches of rivastigmine (Exelon, 
Novartis), nicotine, nitroglycerin (NTG) and topically applied EMLA (eutectic mixture 
of lidocaine/prilocaine). We anticipate that this initial pilot comparison of single doses 
of each medication will catalyze future multi-dose comparisons of the various 
vasodilatory features of these and other drugs.  
 
Methods: With IRB approval, 10 healthy volunteers were monitored with PPG at the 
time each transdermal patch was applied and every 8 minutes afterwards for a total of 
40 minutes. 1x1 cm portions of patches of rivastigmine, nicotine, and NTG were placed 
and monitored on different sites of the forehead. Another site was isolated and 
pretreated 6 hours earlier with EMLA, since this drug requires many hours to induce 
vasodilation.1 All voltage changes were changed to ACmults, i.e., in multiples of the 
change in voltage associated with delivery of the stroke volume to the given site under 
resting conditions2. A linear mixed model was used to compare patch effects on 
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maximum change in AC, DC, and ΔAC/ΔDC. This model accounts for the variance that 
can be attributed to an individual’s multiple measurements within an unstructured 
covariance matrix. A p-value <0.05 was given to be statistically significant. Data were 
expressed as mean within a 95% confidence interval. 
 
Results: The max ∆AC change for each drug were significantly different from that of 
its control while only the max ∆DC of NTG was significantly greater than that of its 
control. Changes in the ΔAC/ΔDC ratio were found to be inconsistent. Rivastigmine 
and control had significantly lower ΔAC/ΔDC values at 8 minutes compared to that of 
EMLA; the differences were not significant at following time points.  
 
Discussion: These results may provide some insight into the cardiovascular effects of 
the study agents used. NTG, a direct NO donor, caused significant increases in AC 
(arteriolar) and DC (venous) values. Acting at the pre/post ganglionic junction of local 
parasympathetic pathways to the region of the precapillary sphincter, nicotine caused a 
significant increase in AC, whereas the change in DC was not found to be significant. 
Rivastigmine, which inhibits the metabolic degradation of acetylcholine, caused a 
selective increase in AC.  The local anesthetic (EMLA) caused a significant increase in 
AC.  Rivastigmine caused significantly lower ΔAC/ΔDC ratio at 8 minutes when 
compared to EMLA (which had been on for 6 hours previously). At >16 minutes, the 
ΔAC/ΔDC values of rivastigmine and EMLA did not differ significantly, findings that 
may reflect the time needed for acetylcholine to to increase over time via the inhibition 
of its breakdown as opposed to an immediate introduction of additional agonist via the 
nicotine or NTG patch. Future studies using different and/or additional drug 
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combinations may help give further insight into the convoluted physiology of the 
microvasculature. 
 
*The above abstract was presented at the American Society of Anesthesiologists 2016 
annual meeting. 
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INTRODUCTION 
 
Photoplethysmography (PPG) is a simple and low-cost optical technique that is 
used non-invasively at the surface of the skin to detect blood volume changes in 
microcirculation [1]. Photoplethysmography was first rendered in 1938 by Hertzman of 
the United States and Matthes and Hauss of Germany and has since been extensively 
studied and used in a wide range of commercially available medical devices for 
measuring oxygen saturation, blood pressure and cardiac output, assessing autonomic 
function and detecting peripheral vascular disease [2, 3]. 
Since its conception, the PPG has contributed to improvements in clinical 
practice but has also continued to mystify physicians and researchers. Though the 
origins of the PPG signal are not fully understood, it is generally accepted that they can 
provide valuable information about the cardiovascular system [4]. In the 1970s, a major 
advancement in the clinical use of a PPG-based technology came when its utility as a 
non-invasive method for monitoring patients’ arterial oxygen saturation was realized 
[5]. Since then, the PPG has been used in various other clinical applications and is now 
in several commercially available medical devices - pulse oximeters, vascular 
diagnostics, and digital beat-to-beat blood pressure measurement systems. This success 
has been possible despite the characteristics of the PPG waveform from being 
thoroughly studied and understood; more research needs to be done to uncover the 
myriad of physiologically relevant information contained in the PPG. 
This study will build on previous work done in our laboratory that converts 
changes in PPG voltage to changes in blood flow in the local environment secondary to 
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locally targeted vasodilators. We will use PPG monitoring to see if any differences can 
be seen in arterial and venous blood flow between different vasodilatory drugs. 
 
PHOTOPLETHYSMOGRAPHY 
 
 PPG uses a light source to illuminate tissue (usually the skin) and a 
photodetector that measures small variations in light intensity associated with changes 
in perfusion in the local microvasculature. It is often used at the red or near infrared 
wavelength to facilitate measurement of blood flow. The photodetector converts light 
energy into an electrical current, which is connected to low noise electronic circuitry 
that includes a transimpedance amplifier and filtering circuitry [3].  
 There are two configurations of photoplethysmography that can be utilized in 
practice. The most common modality is “transmission mode” in which tissue is placed 
between a light-emitting diode and a photodetector, e.g. across a fingertip or earlobe 
(see Figure 1A). A pulse of blood increases both the optical density and path length 
through the illuminated tissue, a process that decreases the light intensity at the 
photodetector. In “reflectance mode,” the photodetector is placed alongside the light-
emitting diode (see Figure 1B) and records the light that returns after being reflected by 
non-hemolyzed red blood cells [6]. 
 
A. B. 
Figure 1. Configurations of PPG in transmission mode (A) and reflection mode (B). 
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The quantitative relation between blood perfusion through an irregular network 
of vessels, and the fraction of photons that pass through the tissue or is reflected, is 
complicated. The Beer-Lambert law gives us a way to understand the PPG waveform in 
more simplistic terms; in other words, assuming a uniform and diffuse layer of blood 
perpendicular to a beam of light and taking into consideration only light absorption (not 
scatter, refraction, reflection), the Beer-Lambert law states that light intensity decays as 
a function of distance exponentially [6]. 
 There are two components to parcel out with regard to the PPG waveform. The 
baseline level of the photoplethysmogram is referred to as the direct current (DC) and is 
a relative index of skin vascularity that is affected by perturbations in thermoregulation, 
respiration, metabolic state, drugs, central and local regulatory mechanisms [6]. This 
baseline is not steady but contains low-frequency oscillations due to changes in 
recruited capillary densities and venous volume fluctuations. These oscillations have 
been found even distal to an arterial tourniquet, which may represent sympathetically 
mediated shifting of blood between different compartments of the peripheral 
microcirculation [7]. The pulsatile waveform attributed to changes in blood volume 
generated by individual heart beats is referred to the alternative current (AC) and is a 
manifestation of cardiac stroke volume typically seen around 1 Hz (See Figure 2). This 
is, as stated, superimposed on top of the slowly varying DC baseline which relates more 
to tissue (See Figure 3) including skin, bone, muscle and average blood volume [3].  
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Figure 2. The pulsatile (AC) component of the PPG and corresponding 
electrocardiogram (ECG) 
 
 
Figure 3. AC & DC components of the PPG 
 
With regard to most commercial pulse oximeters however, the baseline PPG 
waveform usually has been electronically processed to remove baseline vacillations and 
reduce signal distortions to yield a photoplethysmogram that appears “cleaner.” There is 
no one standard method for removing oscillations in the DC baseline; in fact, many 
processing algorithms vary among manufacturers and are often proprietary. Some also 
“autoscale” the PPG waveform so that the amplitude of the signal is adjusted to fit 
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neatly in the display window. Unfortunately, this processing removes much of the 
useful information in the PPG waveform. 
 
ASSESSMENT OF ENDOTHELIAL FUNCTION 
 The endothelium is the layer of thin, single layer of cells that line the interior 
surface of blood vessels to form an interface between the circulating blood and the 
vessel wall. These cells line the entire circulatory system from the heart to the capillary. 
Endothelial cells are involved in many aspects of vascular functionality, including 
vasoconstriction and vasodilatation, blood clotting, angiogenesis, atherosclerosis, and 
inflammation [3]. Endothelial dysfunction is considered to be an early event in 
atherosclerosis and is associated with major risk factors for cardiovascular disease. 
Traditionally, endothelial function is assessed non-invasively by an ultrasound to 
measure the brachial artery diameter before and after several minutes of blood flow 
occlusion in the arm [8]. The change in arterial diameter gives an indication of flow 
mediated endothelium-dependent vasodilatation. Unfortunately, the technique is 
operator dependent and requires a high degree of skill, which could limit its usefulness 
for routine clinical assessments. PPG has also shown potential for the assessment of 
endothelial function but is much less costly than the ultrasound approach. The potential 
for PPG assessments to assess vasodilatation has been demonstrated using 
hemodynamic responses to nitroglycerin (NTG) therapy [9]. Understanding the 
physiology of the microvasculature is a vital part of understanding endothelial 
dysfunction, a key component of cardiovascular disease. As nitroglycerin is but one of 
many types of vasodilatory drugs, our laboratory aims to use NTG and other drugs 
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(rivastigmine, nicotine and an eutectic mix of local anesthetics, i.e. EMLA) to further 
refine the PPG as an instrument to better understand what may be occurring at the level 
of the microvasculature in response to specific, locally-targeted vasodilatory drugs. This 
is especially interesting within the context of testing more than one drug at the same 
time and seeing potential additive effects on the local microvasculature.  
To date, sildenafil, commonly known as Viagra, is the most commercially 
successful drug ever launched. As a potent vasodilator, it is prescribed to increase the 
flow of blood to the penis to treat erectile dysfunction. Despite its efficacy or perhaps 
because of it, many have reported on its interaction with NTG, a potent vasodilator 
commonly prescribed to treat heart disease, to produce potentially lethal hypotension. 
Sildenafil, a phosphodiesterase-5 inhibitor (PDE5), blocks the enzyme responsible for 
the breakdown of cyclic GMP. NTG is an exogenous organic nitrate that releases nitric 
oxide (NO) near vascular smooth muscle cells. Nitric oxide activates soluble guanlyl 
cyclase, an enzyme that catalyzes the formation of cGMP from GTP. Thus, by 
inhibiting the breakdown of cGMP, the effect of cGMP-dependent protein kinase G 
(PKG) is potentiated and induces greater vascular smooth muscle relaxation through the 
phosphorylation of myosin light chain kinase (See Figure 4). 
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Figure 4. Mechanism whereby sildenafil induces greater vascular smooth muscle 
relaxation 
 
Because of the potentially lethal risks involved in testing adverse drug reactions, 
effective studies utilizing normal human physiology is difficult. Webb et al found the 
coadministration of sildenafil and isosorbide mononitrate resulted in a significantly 
greater decrease in both sitting and standing blood pressure than that of the 
coadministration of sildenafil and placebo [10]. A double-blind, randomized study led 
by Parker et al also found that doses of intravenous NTG (between 5ug/min to 
80ug/min) infused after 100mg of sildenafil resulted in a 4 to 6mmHg hypotensive 
effect as compared with placebo [11]. However, it would be unwise to extend the results 
of this study to interactions of sublingual NTG with sildenafil or other PDE5 inhibitors. 
It is therefore important to develop a standard model of study that can be used safely 
and consistently in human subjects. 
 
	   14	  
PURPOSE & HYPOTHESIS 
Our laboratory has developed a dual-platform drug model that utilizes 
“micropatches” as a way to test and compare the direct effects of a variety of drugs on 
the level of the microvasculature in conjunction with a drug taken systemically. Such a 
method allows any potential drug interactions to be seen in a localized and controlled 
environment that minimizes systemic risk. Furthermore, activation of multiple systemic 
responses and reflexes, many of which may modulate the effect at the target site, is 
minimized. Thus, the dual-platform drug model is a promising way to evaluate the 
effects of NTG and sildenafil taken conjointly, as well as other drugs which may have a 
different propensity for inducing vasodilation and hypotension.  
Our study is divided into two phases. As NTG, rivastigmine, nicotine and 
EMLA induce vasodilation via different physiological mechanisms, the first phase of 
our study focuses on comparing their vasodilatory effects on the peripheral 
microvasculature without systemic perturbation. In the second phase of our study, we 
will use the dual-platform drug model to determine how these effects change with 
systemic administration of sildenafil. This thesis will focus its attention primarily on the 
first phase as it represents my contribution to a larger study. 
In this study, PPG is used as a noninvasive monitor of arterial and venous 
microcirculation. We compared the effects of transdermal patches of nicotine, 
rivastigmine (dependent upon autonomic pathways and intact endothelium) and NTG 
(endothelium-independent) with topically applied EMLA. Because these drugs act 
through differing pathways, we hypothesize that specific differences in their local 
vasodilatory effects can be captured by information extracted from the PPG waveform. 
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MATERIALS & METHODS 
 
With IRB approval, 10 healthy volunteers were enrolled in a double-blind 
crossover study conducted over two sessions with a one-week washout period in 
between in which subjects were randomized between two days and given either a 
placebo pill or a sildenafil pill. Subjects were 10 healthy medical students. All subjects 
received verbal and written descriptions of the study protocol with associated risks. An 
informed consent approved by the IRB was signed by all volunteers. Though the full 
protocol will be described here, this paper will focus its analysis exclusively on sessions 
where a placebo pill was used. 
During one session, the subject received transdermal translucent patches of 
nitroglycerin, rivastigmine, nicotine and EMLA in conjunction with a placebo pill; on 
the other day, the subject received the same set of patches in conjunction with sildenafil. 
Sildenafil (100mg capsule) and placebo pills were produced and blinded by an external 
research pharmacist. Both pills were designed to look and feel identical and were given 
to experimenters and subjects in the same fashion in order to preserve double-blinding. 
The blinding was broken only after data analysis. 
In order to minimize information bias, the sites at which the patches were 
administered were randomized between subjects. Because sildenafil no longer interacts 
with nitroglycerin 24 hours after sildenafil administration (and may be gone as early as 
four hours after sildenafil intake), we anticipated that repeating the study a week later to 
be a sufficiently long enough washout period to minimize any carryover effect. 
Two hours after sildenafil or placebo administration, we obtained baseline 
readings of microvasculature dilation with PPG. 1x1 cm transdermal patches of 
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nitroglycerin, rivastigmine, nicotine were then placed and monitored on different 
forehead sites randomized between the two sessions, along with a control site that was 
also monitored without any drug. A specific template demarcating this area was utilized 
that allowed for adequate spacing between all drug sites (See Figure 5). New sites on 
the forehead that have not had any drug exposure were then utilized the week after to 
minimize potential confounding and carryover effect. In order to compare data points 
from the two days (placebo vs sildenafil) for each subject, the same measuring probes 
were used to minimize measuring differences that may exist between probes. Of note, 
EMLA came prepackaged as a topical cream; an additional 1x1 cm area of the forehead 
was pretreated with EMLA for 6 hours and removed before PPG monitoring as this 
drug had a longer prodromal phase in comparison.  
 
 
Figure 5. Template for patch application on subject forehead. Red boxes were 
utilized during first session. Green boxes were used during second session to 
minimize potential confounding and carryover effect of drugs. 
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Our research subjects were monitored with fixed gain reflective PPG (ADI 
probe: Novametrix Medical Systems Inc) interfaced via bridge amplifer to data 
acquisition system, LabChart (ADInstruments, Boulder CO), at the time of application 
and every 8 minutes afterwards for 40 minutes with sampling frequency of 200 Hz (See 
Figure 6). Continuous monitoring was not performed in order to minimize any 
confounding risk of probe heating on vasodilation.  
 
Figure 6. PPG sample of a research subject undergoing the experimental protocol for 
nicotine, EMLA and control. Upper three panels show the raw PPG signal. Lower three 
panels show the filtered AC signal. From left to right, columns designate pre-testing 
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baseline, baseline at 0 minutes at initial patch application, 8 minutes afterward, and 16 
minutes afterward. 
 
 
Previous studies from our laboratory have shown that a voltage to volume 
conversion based upon pulsatile volume at rest allows volume monitoring using a PPG 
when resting stroke volume is known (measured or estimated). That is to say, one is 
able to distinguish between arterial and venous components of the PPG signal under 
certain assumptions. Our previous work has shown that PPG monitoring at a site 
relatively devoid of vasoconstrictive activity (e.g., forehead) reveals relative degrees of 
pulsatile and nonpulsatile blood volume similar to the 3000/125 (~24/1) relationship 
between circulating venous volume and stroke volume. Thus, all voltage changes can be 
expressed as “AC multiples at rest,” or “AC equivalents,” i.e., in multiples of the 
change in voltage associated with the pulsatile delivery of the stroke volume to the 
given site under resting conditions [12]. The AC multiple at rest is associated with an 
AC voltage at rest; this voltage then becomes the calibrating voltage that one can then 
use to make sense of changes in AC and DC in terms of multiples of “stroke volume.” 
This estimation is used because AC is independent of background and normalizing to 
the AC found at rest eliminates impact of attenuation. Thus, when a baseline stroke 
volume is available (e.g., 125 ml as measured by echo or estimated from population 
average), change in volume (in ml) can be calculated from the PPG based upon the 
following conversion:  
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Stroke volume at rest = 125 ml = 1 [AC multiples at rest] ~ AC calibrating 
voltage = [AC voltage at rest].  
 
Change in volume (in ml) can be calculated in one of two ways. 
= ‘Given reading in [AC multiples at rest]’ x ‘125 ml/1 [AC multiples at rest]’ 
or  
= ‘Given readings in volts’ x ‘125 ml/[AC voltage at rest]’ 
 
ANALYSIS 
 All PPG waveforms were extracted by ADInstruments LabChart. A linear mixed 
model was used to compare the patch effects on maximum change in AC, maximum 
change in DC, and maximum change in ΔAC/ΔDC. This model accounts for the 
treatment group, day of study, repeated subjects, the sequence of treatment, and the 
variance attributable to an individual’s multiple measurements with an unstructured 
covariance matrix. Sequence of treatment refers to which order the subject received 
sildenafil and placebo on day 1 and day 2 of the study. Subjects were treated as random 
effects in the model. A p-value <0.05 was considered significant. Analyses was 
conducted on the assumption that controls can be pooled together. 
From the raw data sets, the median values of the first 20 data points at each time 
segment for each patch on each day of study were calculated. Median was chosen as the 
statistic to use due to the fact that the sample mean can often be unduly influenced by 
outliers. The 0-minute time segment AC value for each patch on each day of study were 
used as denominators to calculate AC equivalents for all corresponding median AC and 
	   20	  
DC values. The ΔAC and ΔDC values were calculated as changes in raw and AC 
equivalents from the 0-time segment values for each patch.  
Maximum ΔAC and ΔDC values for each patch on each day of study were 
determined from the 0 to 40-minute data for patches NTG, nicotine, Exelon and its 
associated controls. Magnitude comparisons of changes in AC and DC in terms of 
absolute AC equivalents between patches were not done because drug patches weren’t 
dose equivalent. Thus, max changes in the ratio between AC and DC were also obtained 
in similar fashion for each patch since the comparison of a ratio nullifies the dose 
effects of each patch, i.e., the apparent dose of drug that induced a certain change in AC 
should be of the same factor as that which induces the change in DC as well. 
For patches EMLA and its associated control, maximum ΔAC and ΔDC values 
for each patch on each day of study were assumed to be at time segment 0, which was 
compared to a baseline taken 6 hours prior to application.  
 
RESULTS 
As shown in table 1, within the placebo session, the maximum ΔAC (in AC 
equivalents) was 1.211 units higher in Exelon compared to its paired control 
(p=0.0223).  The maximum ΔDC (in AC equivalents) was -5.099 compared to its paired 
control, but this was not statistically significant. The maximum Δ(ΔAC/ΔDC) is 0.174 
higher in Exelon compared to its paired control; this is a marginally significant 
difference (p=0.0554).  
The maximum ΔAC (in AC equivalents) was 1.387 units higher in NTG 
compared to its paired control (p=0.0002).  The maximum ΔDC (in AC equivalents) 
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was 37.479 compared to its paired control (p=0.0037). The maximum Δ(ΔAC/ΔDC) is 
0.001 higher in NTG compared to its paired control; this was not statistically 
significant.  
The maximum ΔAC (in AC equivalents) was 2.352 units higher in EMLA 
compared to its paired control (p<0.0001).  The maximum ΔDC (in AC equivalents) 
and the maximum Δ(ΔAC/ΔDC) was not significantly different compared to its paired 
control. 
The maximum ΔAC (in AC equivalents) was 2.581 units higher in nicotine 
compared to its paired control (p=0.0002).  The maximum ΔDC (in AC equivalents) 
and the maximum Δ(ΔAC/ΔDC) was not significantly different compared to its paired 
control. 
 
Table 1. Comparison of drug patch to control with regard to max ΔAC, max ΔDC, max 
Δ(ΔAC/ ΔDC) within the placebo session (in terms of AC equivalents) 
 
 Max ΔAC 
(AC eq.) 
 Max ΔDC (AC eq.)  Max 
Δ(ΔAC/ΔDC) 
 
Patch 
Estimate 
[95% CI] p-value Estimate [95% CI] p-value 
Estimate [95% 
CI] p-value 
Exelon 
1.211  
[ 0.217, 
2.206] 
0.0223
* 
-5.099  
[-29.378, 19.180] 
0.6460 0.174  
[ -0.005, 0.353] 
0.0554 
NTG 
1.387  
[ 0.862, 
1.911] 
0.0002
* 
37.479  
[ 15.648, 59.309] 
0.0037
* 
0.001  
[ -0.223, 0.225] 
0.9926 
EMLA 
2.352  
[ 1.466, 
3.238] 
0.0002
* 
10.757  
[-28.937, 50.451] 
0.555 0.031  
[ -0.799, 0.862] 
0.9335 
Nicotine 
2.581  
[ 2.098, 
3.063] 
<.0001
* 
34.270  
[ -5.117, 73.658] 
0.0806 -0.224  
[ -0.666, 0.217] 
0.2799 
*Denotes a p-value that is statistically significant 
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When comparing the effects of different drugs, the max change in ΔAC/ΔDC ratio was 
used as a way to control for differing dosing equivalents of drug patches. As shown in 
Table 2, comparisons between all possible combinations of drug patches were 
calculated. Some values are repeated albeit in the opposite direction (e.g., -0.262 vs 
0.262 with regard to EMLA vs Exelon) depending on which drug patch was set as the 
reference of comparison during analysis. As can be seen, there are no significant 
differences between drug patches within the placebo session with regard to max 
Δ(ΔAC/ΔDC). 
Table 2. Comparison of max change of ΔAC/ΔDC between drug patches within the 
placebo session 
 Max Δ(ΔAC/ΔDC)  
Patch Comparison Estimate [95% CI] p-value 
vs Exelon   
EMLA -0.262 [ -0.719, 0.195] 0.2275 
NTG -0.075 [ -0.208, 0.058] 0.2348 
Nicotine -0.016 [ -0.193, 0.161] 0.8414 
   
vs Nicotine   
EMLA -0.246 [ -0.605, 0.113] 0.1558 
Exelon 0.016 [ -0.161, 0.193] 0.8414 
NTG -0.059 [ -0.152, 0.034] 0.1873 
   
vs NTG   
EMLA -0.187 [ -0.563, 0.189] 0.2902 
Exelon 0.075 [ -0.058, 0.208] 0.2348 
Nicotine 0.059 [ -0.034, 0.152] 0.1873 
   
vs EMLA   
Exelon 0.262 [ -0.195, 0.719] 0.2275 
NTG 0.187 [ -0.189, 0.563] 0.2902 
Nicotine 0.246 [ -0.113, 0.605] 0.1558 
 
	   23	  
 
Table 3 compares EMLA at its max effect, which is specifically found at time 0 (PPG 
monitoring directly after removal of EMLA status post pretreatment of 6-hour 
duration), against all other drug patches at 8 minutes, 16 minutes and 24 minutes during 
the placebo session. Again, because of dose equivalency considerations, ΔAC/ΔDC 
ratios were utilized. EMLA was used as the reference group.  
 
Table 3A. Comparison of ΔAC/ΔDC ratios at EMLA time 0 and time 8 minutes for 
other patches during the placebo session. 
 ΔAC/ΔDC within Placebo  
Patch Estimate [95% CI] p-value 
Exelon 
-.07875  
[-.13149,-.02600] 
0.0082* 
NTG 
-.03114  
[-.07383,.011554] 
0.1334 
Nicotine 
.020799  
[-.08800,.129594] 
0.6756 
Control 
-.07716  
[-.14914,-.00518] 
0.0383* 
*Denotes a p-value that is statistically significant 
 
 
As shown in Table 3A, during the placebo session, the ΔAC/ΔDC ratio was -0.079 units 
lower in Exelon at 8 minutes compared to EMLA at 0 minutes (p=0.008). The ratio of 
the control at 8 minutes was 0.08 units lower compared to the ratio of EMLA at 0 
minutes (p=0.04).  
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Table 3B. Comparison of ΔAC/ΔDC ratios at EMLA time 0 and time 16 minutes for 
other patches during the placebo session. 
 ΔAC/ΔDC within Placebo  
Patch Estimate [95% CI] p-value 
Exelon 
.033609  
[-.08899,.156211] 
0.5505 
NTG 
-.03177  
[-.07981,.016262] 
0.1688 
Nicotine 
-.03484  
[-.10243,.032744] 
0.2735 
Control 
-.05746  
[-.11836,.003445] 
0.0616 
 
 
As shown in Table 3B, there were no significant differences between the EMLA 
ΔAC/ΔDC ratio at 0 minutes and the ΔAC/ΔDC ratio for other patches at 16 minutes 
during the placebo session. 
 
Table 3C. Comparison of ΔAC/ΔDC ratios at EMLA time 0 and time 24 minutes for 
other patches during the placebo session. 
 ΔAC/ΔDC within Placebo  
Patch Estimate [95% CI] p-value 
Exel 
-.03907 
[-.10351,.025375] 
0.2035 
NTG 
-.03257 
[-.07733,.012184] 
0.1341 
Nico 
-.02888 
[-.08427,.026507] 
0.2684 
CtrlN 
-.03895 
[-.25341,.175500] 
0.6908 
 
 
As shown in Table 3C, there were no significant differences between the EMLA 
ΔAC/ΔDC ratio at 0 minutes and the ΔAC/ΔDC ratio for other patches at 24 minutes 
during the placebo session. Across these comparisons, EMLA tends to have the highest 
ΔAC/ΔDC ratio, but as mentioned, most of these differences are not significant. 
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DISCUSSION 
 
 
The PPG is a powerful tool replete with information that has yet to be fully 
understood. Given its ability to observe changes in blood circulation in local cutaneous 
tissue, it is a great tool to understand the mechanisms and effects of different drugs at 
the level of the microvasculature. In our study, we aim to understand the differences 
between four locally targeted vasodilators including NTG, nicotine, rivastigmine, and 
EMLA with regard to changes in venous and arterial microcirculation. This study 
attempts to lay the foundational groundwork for future phases and studies in which 
additive drug combinations are “layered” systemically on top of locally targeted drugs. 
This is the concept of the “dual platform” drug model to assess pharmacological 
interactions in a localized and controlled manner that minimizes systemic risk.  
As seen in our results, all four drugs resulted in significant increases in the AC 
component of the PPG as compared to control. For example, in terms of AC equivalents 
or stroke volume equivalents, nicotine showcased the largest AC increase with 2.581 
AC equivalents versus rivastigmine with an increase of 1.211 AC equivalents. If we 
take resting stroke volume to be 125ml, a 2.581 AC equivalent increase is estimated to 
be an increase in 322.625 ml versus 151.375 ml with regard to rivastigmine. Though 
these increases seem to be vastly different, we must remember that our patches are not 
dosed equivalently. A direct comparison of patches that take into consideration dosing 
differences using changes in the ratio of AC and DC does not show the patches to be 
statistically significantly different. This again extends not just to nicotine versus EMLA, 
but to all possible drug comparison combinations in our study. While this conversion is 
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not relevant to local changes in the microvasculature, it may prove valuable in the 
context of challenges and changes in systemic volume. 
Interestingly, NTG was the only drug that resulted in significantly increased 
changes in DC along with significantly increased changes in AC. It is known that 
nitrates predominantly cause the dilation of peripheral veins, and in higher doses, cause 
the dilation of peripheral arteries [13]. As an exogenous organic nitrate, it likely 
releases nitric oxide (NO) near vascular smooth muscle cells both before and after the 
pre-capillary sphincter, acting in conjunction on both the arterial and venous side within 
the local microvasculature. 
Parasympathetic ganglion and post-ganglionic parasympathetic fibers have been 
considered as potential mediators of vasodilation in the peripheral microvasculature 
[14]. Since the arteriole-capillary-venule microvasculature is not a homogeneous 
system, differences in the extent of autonomic innervation, where endogenous NO is 
produced and where NO can act may influence the extent of vasodilation measured. In 
contrast to NTG, acetylcholine (ACh) and nicotine administered peripherally via 
micropatches are likely activators of postganglionic parasympathetic fibers, which 
induce the release of ACh [15]. Nitric oxide synthase is constitutively present in 
endothelial cells; ACh induces endothelium-dependent vasodilation and stimulates 
nitric oxide synthase to produce endogenous NO, producing vasodilation in areas with 
vascular smooth muscle tissue [16]. Thus, a transdermal acetylcholinesterase inhibitor 
like rivastigmine (or nicotine directly) will be able to prolong the effects of ACh within 
the parasympathetic ganglion and induce vasodilation through endothelium-dependent 
processes. Our study seems to show that these postganglionic parasympathetic fibers 
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may be more predominantly concentrated at (rather than beyond) the pre-capillary 
sphincter, thus resulting in more of an arterial vasodilatory effect.  
On the other hand, EMLA (an eutectic mix of local anesthetics), which blocks 
all sodium channels in nerves, would block transmission of all electrical impulses in the 
periphery [17]. Since blood vessels are held under a certain level of constant 
vasoconstriction through sympathetic activity, the release of this constriction via EMLA 
produces vasodilation where sympathetic activity was seen previously. Though we are 
not able to discern or isolate the potential for off-target effects that EMLA may produce 
within the local area, our study seems to indicate that the primary measurable 
vasodilatory effect was isolated to the arterial microcirculatory system before the pre-
capillary sphincter.  
When we use EMLA as a reference for comparison, interesting temporal 
relationships are observed. Because of the time it takes for EMLA to permeate through 
the upper epidermal layer, we pretreated a designated site 6 hours before our main 
experimental protocol. This 6-hour timeframe was determined through repeated 
experimentation as the minimum amount of time needed for measurable effects to be 
seen via PPG. Thus, at “time 0” when the other drug patches were placed and the 
EMLA cream removed before monitoring (due to the cream being opaque in nature), 
PPG measurements of the EMLA site should demonstrate maximal vasodilation, an 
effect confirmed by our experimental protocol. As expected, the vasodilatory effects of 
a “control patch” was significantly lower than that of EMLA at its peak effect as 
measured by changes in the AC to DC ratio. Of note, the vasodilatory effects of 
rivastigmine at 8 minutes were also significantly lower than that of EMLA at time 0; 
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this difference disappeared at 16 minutes and beyond. It is also important to note that 
this phenomenon was not observed in any other drug patch, i.e., the effects of other 
drug patches were not significantly different from that of EMLA at 8 minutes or 
beyond. Rivastigmine is unique among the drugs that we tested as the sole 
acetylcholinesterase inhibitor [18]; it prolongs the effect of of ACh within the 
parasympathetic ganglion by preventing its breakdown and thereby induce vasodilation 
through endothelium-dependent processes. We hypothesize that this particular temporal 
“delay of effect” with regard to rivastigmine at 8 minutes represents a sort of 
“enzymatic lag” that may reflect the time needed for acetylcholine to “build-up” in the 
synaptic cleft via the inhibition of its breakdown as opposed to an immediate 
introduction of additional agonist via the nicotine or NTG patch. Further repeated 
testing in the future will be conducted to confirm this hypothesis.  
A main limitation of this study revolves around the use of the ADI probe, a 
research PPG device that unfortunately causes local tissue warming and thus, 
potentially introduces a source of external vasodilation unrelated to the drug patches 
themselves. We tried to remedy this issue by using the probe only in one minute 
intervals (every 8 minutes) to minimize probe heating; still, it is uncertain how much 
variability this may have introduced into the study. Development of a probe that can 
provide a DC signal without relying on a research probe that causes local tissue 
warming would be ideal.  
As stated, this paper represents the first phase of study in which we lay the 
foundation for understanding the complex physiology of the microvasculature. Future 
analysis will explore this environment with different and/or additive drug combinations 
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to further elucidate the physiological interaction between several different drug 
combinations in a safe and reproducible manner, particularly in conjunction with 
sildenafil taken systemically. Evidence indicates that Alzheimer’s disease may be 
derived from a vascular pathology characterized by cerebral hypoperfusion and that 
pharmacotherapy that improves cerebral perfusion often lowers neurodegenerative 
symptoms [19]. If it is possible to find a drug combination that can maximally induce 
vasodilation within the microvasculature while minimizing systemic hypotensive risk, 
clinical applications may exist for Alzheimer’s and other more well known 
cardiovascular diseases.  
 
CONCLUSION 
In summary, the PPG may be used as a non-invasive monitor of arterial and venous 
microcirculation. We aimed to better elucidate the effects of various transdermal 
vasodilators on the forehead microvasculature and understand the underlying 
mechanisms at work for each drug. Such a study lays the groundwork for future 
experiments exploring potential drug interactions in a safe and reproducible manner 
devoid of systemic adverse effects.  
 
 
 
 
 
 
	   30	  
REFERENCES  
 
1. Challoner A V J 1979 Photoelectric plethysmography for estimating cutaneous 
blood flow Non-Invasive Physiological Measurements vol 1 ed P Rolfe 
(London: Academic) pp 125–51 
2. Hertzman, A.B., The blood supply of various skin areas as estimated by the 
photoelectric plethysmograph. Am J Physiol, 1938. 124(2): p. 328. 
3. Allen, John. “Photoplethysmography and its application in clinical physiological 
measurement.” IOP Science, vol. 28, no. 3, 20 Feb. 2007, 
doi:https://doi.org/10.1088/0967-3334/28/3/R01. 
4. Kamal A A, Harness J B, Irving G and Mearns A J 1989 Skin 
photoplethysmography—a review Comp. Method. Prog. Biomed. 28 257–69 
5. Aoyagi T, Kiahi M, Yamaguchi K and Watanabe S 1974 Improvement of the 
earpiece oximeter Abstracts of the 13th Annual Meeting of the Japanese Society 
of Medical Electronics and Biological Engineering 90–1 
6. Reisner, A., et al., Utility of the photoplethysmogram in circulatory monitoring. 
Anesthesiology, 2008. 108(5): p. 950-958. 
7. Nitzan M, Faib I, Friedman H: Respiration-induced changes in tissue blood 
volume distal to occluded artery, measured by photoplethysmography. J Biomed 
Opt 2006; 11:040506 
8. Celemajer D S, Sorensen K E, Gooch V M, Spiegelhalter D J, Miller O I, 
O’Sullivan I, Lloyd J K and Deanfield J E 1992 Non-invasive detection of 
endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 
340 1111–5 
9. Lund F 1986 Digital pulse plethysmography (DPG) in studies of the 
hemodynamic response to nitrates—a survey of recording methods and 
principles of analysis Acta Pharmacol. Toxicol. 59 (Suppl. VI) 79–96 
10. Webb DJ, Muirhead GJ, Wulff M, et al: “Sildenafil citrate potentiates the 
hypotensive effects of nitric oxide donor drugs in male patients with stable 
angina.” J Am Coll Cardiol 2000; 36:25–31 
11. Parker JD, Bart BA, Webb DJ, et al: Safety of intravenous nitroglycerin after 
administration of sildenafil citrate to men with coronary artery disease: A 
double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med 
2007; 35:1863–1868 
12. Liang, I-Hsun. “Distinguishing Arterial and Venous Components of 
Plethysmographic (PPG) Signals.” ASA Abstracts Meeting, 5 Mar. 2015. 
13. Torfgard, KE. “Mechanisms of action of nitrates.” Cardiovascular Drugs 
Therapy, vol. 5, no. 701, ser. 17, 8 Oct. 1994. 17 
14. Fundin, B.t., et al. “Different distributions of the sensory and autonomic 
innervation among the microvasculature of the rat mystacial pad.” The Journal 
of Comparative Neurology, vol. 389, no. 4, 1997, pp. 545–568., 
doi:10.1002/(sici)1096-9861(19971229)389:4 
15. Paton, W. D. M., et al. “The mechanism of acetylcholine release from 
parasympathetic nerves.” The Journal of Physiology, vol. 215, no. 3, Jan. 1971, 
pp. 819–848., doi:10.1113/jphysiol.1971.sp009500. 
	   31	  
16. Hodgson, J. M., and J. J. Marshall. “Direct vasoconstriction and endothelium-
Dependent vasodilation. Mechanisms of acetylcholine effects on coronary flow 
and arterial diameter in patients with nonstenotic coronary arteries.” Circulation, 
vol. 79, no. 5, Jan. 1989, pp. 1043–1051., doi:10.1161/01.cir.79.5.1043. 
17. Buckley, Micaela M., and Paul Benfield. “Eutectic Lidocaine/Prilocaine 
Cream.” Drugs, vol. 46, no. 1, 1993, pp. 126–151., doi:10.2165/00003495-
199346010-00008. 
18. Srinivas, Nuggehally R. “Transdermal Rivastigmine Delivery for Alzheimer 
Disease.” Clinical Neuropharmacology, vol. 39, no. 4, 2016, pp. 169–177., 
doi:10.1097/wnf.00 
19. Torre, Jack C De La. “Cerebral Hypoperfusion, Capillary Degeneration, and 
Development of Alzheimer Disease.” Alzheimer Disease and Associated 
Disorders, vol. 14, no. Supplement, 2000, doi:10.1097/00002093 
 
